Get the Stockscreener App
2.88
1.06%
0.04
Repare Therapeutics Inc stock is traded at $2.88, with a volume of 11,992.
It is up +1.06% in the last 24 hours and down -20.28% over the past month.
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations. The company derives maximum revenue from Canada.
See More
Previous Close:
$2.84
Open:
$2.9
24h Volume:
11,992
Relative Volume:
0.11
Market Cap:
$123.71M
Revenue:
$51.13M
Net Income/Loss:
$-93.80M
P/E Ratio:
-19.20
EPS:
-0.15
Net Cash Flow:
$-129.10M
1W Performance:
-11.69%
1M Performance:
-20.28%
6M Performance:
-15.59%
1Y Performance:
-39.71%
1-Day Range:
$2.82
$2.93
1-Week Range:
$2.75
$3.25
52-Week Range:
$2.71
$8.49
Repare Therapeutics Inc Stock (RPTX) Company Profile
Name
Repare Therapeutics Inc
Sector
Industry
Phone
(857) 412-7018
Address
7171 FREDERICK BANTING, SAINT-LAURENT, QC
Compare RPTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| RPTX | 2.875 | 123.71M | 51.13M | -93.80M | -129.10M | -0.15 |
| VRTX | 447.18 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 741.71 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 589.39 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 248.84 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 103.36 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Repare Therapeutics Inc Stock (RPTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-09-23 | Upgrade | Stifel | Hold → Buy |
| Feb-03-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-06-23 | Initiated | CapitalOne | Overweight |
| Apr-12-22 | Downgrade | Stifel | Buy → Hold |
| Mar-17-22 | Resumed | Goldman | Buy |
| Sep-23-21 | Initiated | Stifel | Buy |
| Sep-13-21 | Initiated | H.C. Wainwright | Buy |
| Jun-28-21 | Initiated | Guggenheim | Buy |
| Mar-01-21 | Initiated | Berenberg | Buy |
| Oct-28-20 | Initiated | Northland Capital | Outperform |
| Jul-14-20 | Initiated | Cowen | Outperform |
| Jul-14-20 | Initiated | Goldman | Neutral |
| Jul-14-20 | Initiated | Morgan Stanley | Overweight |
| Jul-14-20 | Initiated | Piper Sandler | Overweight |
View All
Repare Therapeutics Inc Stock (RPTX) Latest News
Analysts' Revenue Estimates For Repare Therapeutics Inc. (NASDAQ:RPTX) Are Surging Higher - Simply Wall St
Industry Analysts Just Made A Notable Upgrade To Their Repare Therapeutics Inc. (NASDAQ:RPTX) Revenue Forecasts - Yahoo Finance
Repare Therapeutics partners with NCI on cancer drug By Investing.com - Investing.com Australia
Press Release Service: Repare Therapeutics Announces Agreement with the US National Cancer Institute to Advance the Development of Camonsertib - CRISPR Medicine News
Repare Therapeutics Announces Agreement with the US National Cancer Institute to Advance the Development of Camonsertib - BioSpace
Repare Therapeutics partners with NCI on cancer drug - Investing.com India
Repare Therapeutics Partners with NCI to Advance Breakthrough Cancer Drug Camonsertib | RPTX Stock News - StockTitan
Repare Therapeutics (NASDAQ:RPTX) Earns "Buy" Rating from HC Wainwright - MarketBeat
Repare Therapeutics Reports Q3 2024 Progress and Outlook - TipRanks
Repare Therapeutics Provides Business and Clinical Update and Reports Third Quarter 2024 Financial Results - CRISPR Medicine News
Layoff Tracker: Compass Pathways to Lay Off 30% of Employees - BioSpace
Repare Therapeutics (NASDAQ:RPTX) Receives "Buy" Rating from HC Wainwright - MarketBeat
Repare Therapeutics’ individualised anaemia management trial shows promise - Yahoo Finance
Press Release Service: Repare Therapeutics Announces Updated Positive Safety and Tolerability Results from the Phase 1 MYTHIC Clinical Trial - CRISPR Medicine News
Repare Therapeutics Announces Updated Positive Safety and Tolerability Results from the Phase 1 MYTHIC Clinical Trial - BioSpace
Repare Therapeutics reports progress in cancer trial - Investing.com India
RPTX Stock Up as Dosing Begins in Solid Tumor Study for Combo Drug - MSN
Dimensional Fund Advisors LP Sells 27,504 Shares of Repare Therapeutics Inc. (NASDAQ:RPTX) - Defense World
Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-3467, a Polθ ATPase Inhibitor - CRISPR Medicine News
Repare Therapeutics doses first subject in Phase I solid tumour trial - Yahoo! Voices
Repare Therapeutics begins trial for novel cancer drug By Investing.com - Investing.com Australia
Marshall Wace LLP Takes Position in Repare Therapeutics Inc. (NASDAQ:RPTX) - Defense World
Repare Therapeutics Inc. Doses First Patient in Phase 1 Clinical Trial of RP-3467, a Pol? ATPase Inhibitor - Marketscreener.com
There's No Escaping Repare Therapeutics Inc.'s (NASDAQ:RPTX) Muted Revenues Despite A 35% Share Price Rise - Simply Wall St
XTX Topco Ltd Makes New Investment in Repare Therapeutics Inc. (NASDAQ:RPTX) - Defense World
Repare Therapeutics reports promising trial results for cancer drug - Investing.com India
Investing in Repare Therapeutics Inc (RPTX) might be an excellent idea, but the stock is currently overvalued/undervalued – US Post News - US Post News
Repare Therapeutics Inc (RPTX)’s Ratio Roundup: Key Metrics for Trailing Twelve Months - The Dwinnex
Press Release Service: Repare Therapeutics Announces Phase 1 Data Highlighting Camonsertib in Combination with Radiotherapy Treatment Presented at the ASTRO Annual Meeting - CRISPR Medicine News
Repare Therapeutics reports promising trial results for cancer drug By Investing.com - Investing.com South Africa
Repare Therapeutics Announces Phase 1 Data Highlighting Camonsertib in Combination with Radiotherapy Treatment Presented at the ASTRO Annual Meeting - BioSpace
Stocks to Watch: CVS Health, PepsiCo, Repare Therapeutics - MarketWatch
Repare Therapeutics Gets Encouraging Early Phase 1 Data for Camonsertib - MarketWatch
Repare Therapeutics Inc. (NASDAQ:RPTX) Shares Purchased by Blue Owl Capital Holdings LP - MarketBeat
Repare Therapeutics Inc. (NASDAQ:RPTX) is definitely on the radar of institutional investors who own 36% of the company - Yahoo Finance
Replimune Group (NASDAQ:REPL) Stock Price Up 3.8% on Analyst Upgrade - MarketBeat
Financial Metrics Unveiled: Replimune Group Inc (REPL)’s Key Ratios in the Spotlight - The Dwinnex
Repare Therapeutics Inc Stock (RPTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.42%
0.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):